Literature DB >> 17381463

Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells.

S Gerdes1, K Shakery, U Mrowietz.   

Abstract

BACKGROUND: Psoriasis is a chronic inflammatory skin disorder in which T-cell-mediated immune responses are thought to play a prominent role. Fumaric acid esters (FAEs) have proved to be an effective systemic treatment for psoriasis. The FAE dimethylfumarate (DMF) strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Additionally, it has been demonstrated that the nuclear translocation of the activated transcription factor nuclear factor kappaB (NF-kappaB) is inhibited in human endothelial cells and fibroblasts activated with tumour necrosis factor-alpha. The NF-kappaB pathway plays a major role in regulating inflammatory cytokine production as well as in cell differentiation and apoptosis. T-cell survival is also dependent on the activation of NF-kappaB and it has been demonstrated in vitro that DMF is an inducer of apoptosis in human T cells. The influence of FAEs on the expression of nuclear transcription factors in T cells has not yet been investigated.
OBJECTIVES: The effects of DMF and its main metabolite, methylhydrogenfumarate (MHF), were assessed on the nuclear binding of NF-kappaB, nuclear factor of activated T cells (NF-AT) and CCAAT/enhancer binding protein beta (C/EBPbeta) in purified human T cells.
METHODS: To examine the effect of DMF and MHF on the nuclear binding of NF-kappaB, NF-AT and C/EBPbeta in human T cells and fibroblasts, an enzyme-linked immunosorbent assay (ELISA) was used. The binding activity of these transcription factors was measured by its absorbance in an ELISA plate reader at 450 nm. Conspicuous results were confirmed by performing electrophoretic mobility shift assays.
RESULTS: DMF inhibited nuclear binding of NF-kappaB1, but not of NF-AT or C/EBPbeta, in purified human T cells. No effect of MHF on any of these transcription factors could be seen. To verify our results, we used the same assay to show the inhibitory effect on the nuclear binding of NF-kappaB1 in human fibroblasts (as previously published).
CONCLUSIONS: The results of this study provide evidence for a specific effect of DMF on NF-kappaB. The data support previous results where NF-kappaB-dependent mediators and surface molecules were suppressed by DMF, but not those activated by other nuclear transcription factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17381463     DOI: 10.1111/j.1365-2133.2007.07779.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  23 in total

1.  Sex Bias in Pathogenesis of Autoimmune Neuroinflammation: Relevance for Dimethyl Fumarate Immunomodulatory/Anti-oxidant Action.

Authors:  Zorica Stojić-Vukanić; Jelena Kotur-Stevuljević; Mirjana Nacka-Aleksić; Duško Kosec; Ivana Vujnović; Ivan Pilipović; Mirjana Dimitrijević; Gordana Leposavić
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

2.  Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis.

Authors:  Oliver Oey; Padmashree Rao; Magdalena Luciuk; Carly Mannix; Natasha M Rogers; Priyanka Sagar; Annette Wong; Gopala Rangan
Journal:  Exp Biol Med (Maywood)       Date:  2018-02-13

Review 3.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

4.  Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.

Authors:  Jan P Nicolay; Karin Müller-Decker; Anne Schroeder; Markus Brechmann; Markus Möbs; Cyrill Géraud; Chalid Assaf; Sergij Goerdt; Peter H Krammer; Karsten Gülow
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

5.  Dimethyl Fumarate Limits Neuroinflammation and Oxidative Stress and Improves Cognitive Impairment After Polymicrobial Sepsis.

Authors:  Graciela Freitas Zarbato; Mariana Pereira de Souza Goldim; Amanda Della Giustina; Lucinéia Gainski Danielski; Khiany Mathias; Drielly Florentino; Aloir Neri de Oliveira Junior; Naiana da Rosa; Ana Olivia Laurentino; Taina Trombetta; Maria Luiza Gomes; Amanda Valnier Steckert; Ana Paula Moreira; Patricia Fernanda Schuck; Jucelia Jeremias Fortunato; Tatiana Barichello; Fabricia Petronilho
Journal:  Neurotox Res       Date:  2018-04-30       Impact factor: 3.911

Review 6.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

7.  Emerging disease-modifying therapies in multiple sclerosis.

Authors:  Jai Perumal; Omar Khan
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

8.  The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1.

Authors:  Shao Xia Lin; Lucia Lisi; Cinzia Dello Russo; Paul E Polak; Anthony Sharp; Guy Weinberg; Sergey Kalinin; Douglas L Feinstein
Journal:  ASN Neuro       Date:  2011-04-07       Impact factor: 4.146

Review 9.  Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?

Authors:  Petra Seidel; Michael Roth
Journal:  Mediators Inflamm       Date:  2013-03-27       Impact factor: 4.711

10.  Fumaric acid esters in dermatology.

Authors:  Uwe Wollina
Journal:  Indian Dermatol Online J       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.